论文部分内容阅读
目的:通过检测血清中AFP,AFP-L3和GP73,探讨联合检测该三项肿瘤标志物对原发性肝癌诊断的临床价值。方法:通过微柱离心法对病人血清AFP-L3进行分离,并用化学发光法进行AFP定量检测并计算AFP-L3%、病人总AFP,利用定量ELISA检测病人血清中GP73含量。结果:肝癌病人组AFP、AFP-L3和GP73含量均显著高于良性肝病组和正常对照组。且联合检测AFP、AFP-L3和GP73的阳性检测率达96%。结论:通过三项肿瘤指标联合检测,可以提高肝癌病人检测率,有利于临床尽早发现原发性肝癌,可以作为肝癌筛查指标。
Objective: To explore the clinical value of combined detection of AFP-L3 and GP73 in the diagnosis of primary liver cancer by detecting the three tumor markers. Methods: The serum AFP-L3 was separated by micro-column centrifugation. The AFP-L3% and AFP were detected by chemiluminescence. The level of GP73 in serum was detected by quantitative ELISA. Results: The levels of AFP, AFP-L3 and GP73 in patients with liver cancer were significantly higher than those in benign liver disease group and normal control group. And the combined detection of AFP, AFP-L3 and GP73 positive detection rate of 96%. Conclusion: The combined detection of three tumor markers can improve the detection rate of liver cancer patients, which is helpful for the early detection of primary liver cancer in clinic and can be used as a screening index for liver cancer.